Bilateral versus unilateral cases of chronic rhinosinusitis with nasal polyps have notable clinical and laboratory ...

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Image Source: Zacks Investment Research Type II inflammation is responsible for CRSwNP experienced by more than 80% of ...

This approval marks the third indication for mepolizumab in China and offers patients a non-surgical treatment alternative to systemic corticosteroids and surgery. The approval is based on ...

This inflammation pathway affects most patients with difficult-to-treat asthma, increasing the risk of exacerbations and hospitalization. It is also found in up to 80% of people with CRSwNP ...